Ramon Cacabelos

Summary

Affiliation: EuroEspes Biomedical Research Center
Country: Spain

Publications

  1. ncbi request reprint Genomics and pharmacogenomics of brain disorders
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Corunna, Spain
    Curr Pharm Biotechnol 13:674-725. 2012
  2. ncbi request reprint Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Methods Find Exp Clin Pharmacol 29:1-91. 2007
  3. ncbi request reprint Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics
    Ramon Cacabelos
    Institute for CNS Disorders, EuroEspes Biomedical Research Center, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Coruna, Spain
    Curr Alzheimer Res 4:479-500. 2007
  4. doi request reprint Pharmacogenomics and therapeutic prospects in dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Eur Arch Psychiatry Clin Neurosci 258:28-47. 2008
  5. ncbi request reprint Molecular genetics of Alzheimer's disease and aging
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, La Coruna, Spain
    Methods Find Exp Clin Pharmacol 27:1-573. 2005
  6. ncbi request reprint Pharmacogenomics and therapeutic prospects in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Expert Opin Pharmacother 6:1967-87. 2005
  7. doi request reprint Influence of pharmacogenetic factors on Alzheimer's disease therapeutics
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Spain
    Neurodegener Dis 5:176-8. 2008
  8. doi request reprint Pharmacogenomics and therapeutic strategies for dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, 15165 Bergondo, Coruna, Spain
    Expert Rev Mol Diagn 9:567-611. 2009
  9. doi request reprint Pharmacogenomic protocols in CNS disorders and dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Coruna, Spain
    Neurodegener Dis 7:167-9. 2010
  10. doi request reprint Genomics and pharmacogenomics of dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Bergondo, Coruna, Spain
    CNS Neurosci Ther 17:566-76. 2011

Collaborators

  • Jerzy Leszek
  • Masatoshi Takeda
  • Ryouhei Ishii
  • Ryota Hashimoto
  • M Windisch
  • Lucia Fernandez-Novoa
  • X Anton Alvarez
  • Lola Corzo
  • Leonides Canuet
  • Iván Tellado
  • Manuel García-Fantini
  • Verónica Couceiro
  • Antón Alvarez
  • Jesus Figueroa
  • Carolina Sampedro
  • Herbert Moessler
  • Manuel Aleixandre
  • Raquel Zas
  • Valter R M Lombardi
  • Carmen Fraile
  • Dafin Muresanu
  • Andres Gonzalez
  • Carolina Sanpedro
  • Susana Rodriguez
  • Victor Pichel
  • Dulce Arias
  • Valter Lombardi
  • Ignacio Etcheverría
  • Miguel Varela
  • Marta Laredo
  • Paula Pérez
  • Angeles Hernandez

Detail Information

Publications28

  1. ncbi request reprint Genomics and pharmacogenomics of brain disorders
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Corunna, Spain
    Curr Pharm Biotechnol 13:674-725. 2012
    ..The incorporation of genomic medicine procedures and pharmacogenomics into clinical practice, together with educational programs for the correct use of medication, must help to optimize therapeutics in CNS disorders...
  2. ncbi request reprint Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Methods Find Exp Clin Pharmacol 29:1-91. 2007
    ..The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety...
  3. ncbi request reprint Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics
    Ramon Cacabelos
    Institute for CNS Disorders, EuroEspes Biomedical Research Center, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Coruna, Spain
    Curr Alzheimer Res 4:479-500. 2007
    ..From these data, it can be postulated that pharmacogenetic and pharmacogenomic factors are responsible for 75-85% of the therapeutic response in AD patients treated with conventional drugs...
  4. doi request reprint Pharmacogenomics and therapeutic prospects in dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Eur Arch Psychiatry Clin Neurosci 258:28-47. 2008
    ....
  5. ncbi request reprint Molecular genetics of Alzheimer's disease and aging
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, La Coruna, Spain
    Methods Find Exp Clin Pharmacol 27:1-573. 2005
    ..Furthermore, the pharmacogenomics of Alzheimer's disease may contribute in the future to optimize drug development and therapeutics, increasing efficacy and safety, and reducing side-effects and unnecessary costs...
  6. ncbi request reprint Pharmacogenomics and therapeutic prospects in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Expert Opin Pharmacother 6:1967-87. 2005
    ....
  7. doi request reprint Influence of pharmacogenetic factors on Alzheimer's disease therapeutics
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Spain
    Neurodegener Dis 5:176-8. 2008
    ..The incorporation of pharmacogenetic protocols into AD research and clinical practice can foster therapeutics optimization by improving drug efficacy and safety...
  8. doi request reprint Pharmacogenomics and therapeutic strategies for dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, 15165 Bergondo, Coruna, Spain
    Expert Rev Mol Diagn 9:567-611. 2009
    ....
  9. doi request reprint Pharmacogenomic protocols in CNS disorders and dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Coruna, Spain
    Neurodegener Dis 7:167-9. 2010
    ....
  10. doi request reprint Genomics and pharmacogenomics of dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Bergondo, Coruna, Spain
    CNS Neurosci Ther 17:566-76. 2011
    ....
  11. doi request reprint Genomics and pharmacogenomics of schizophrenia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, 15165 Bergondo, Coruna, Spain
    CNS Neurosci Ther 17:541-65. 2011
    ..Consequently, the incorporation of pharmacogenomic procedures both to drugs in development and drugs on the market would help to optimize therapeutics in SCZ and other central nervous system (CNS) disorders...
  12. doi request reprint Pharmacogenomics in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Methods Mol Biol 448:213-357. 2008
    ..The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety...
  13. ncbi request reprint Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, EuroEspes Biotechnology EBIOTEC, Coruna, Spain and Department of Biotechnology and Genomics, Camilo José Cela University, Madrid, Spain
    Neurol Res 26:459-80. 2004
    ....
  14. ncbi request reprint Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications
    Ramon Cacabelos
    Department of Clinical Neuroscience, EBIOTEC, EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Neurol Res 25:567-80. 2003
    ..In this regard, cerebrovascular dysfunction should be considered a potential therapeutic target in dementia...
  15. ncbi request reprint Decreased levels of serum nitric oxide in different forms of dementia
    Lola Corzo
    Department of Clinical Biochemistry, EuroEspes Biomedical Research Center, Santa Marta de Babío s n, 15166 Bergondo, La Coruna, Spain
    Neurosci Lett 420:263-7. 2007
    ..Our data suggest that NOx may contribute to the pathogenesis of dementia through a process mediated by HDL-cholesterol...
  16. pmc Resting-state network disruption and APOE genotype in Alzheimer's disease: a lagged functional connectivity study
    Leonides Canuet
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Corunna, Spain
    PLoS ONE 7:e46289. 2012
    ..This study aimed at identifying spatial patterns and effects of APOE genotype on resting-state oscillations and functional connectivity in patients with AD, using a physiological connectivity index called "lagged phase synchronization"...
  17. ncbi request reprint The application of functional genomics to Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Pharmacogenomics 4:597-621. 2003
    ..Consequently, the understanding of functional genomics in AD will foster productive pharmacogenomic studies in the search for effective medications and preventive strategies in AD...
  18. ncbi request reprint Pharmacogenomics for the treatment of dementia
    Ramon Cacabelos
    From the EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, La Coruna, Spain
    Ann Med 34:357-79. 2002
    ..The pharmacogenomics of AD may contribute in the future to optimise drug development and therapeutics, increasing efficacy and safety, and reducing side-effects and unnecessary costs...
  19. pmc Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, 15165 Bergondo, Spain
    Int J Alzheimers Dis 2012:518901. 2012
    ..APOE and CYP2D6 may cooperate, as pleiotropic genes, in the metabolism of drugs and hepatic function. The introduction of pharmacogenetic procedures into AD pharmacological treatment may help to optimize therapeutics...
  20. ncbi request reprint Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia
    Ramon Cacabelos
    EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Madrid, Spain
    Pharmacogenomics 5:1049-105. 2004
    ..All these genotypic and phenotypic variations bring about important consequences for the pharmacogenomics of AD...
  21. ncbi request reprint Genetic variation and pharmacogenomics in Alzheimer disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Spain
    Seishin Shinkeigaku Zasshi 105:47-67. 2003
  22. ncbi request reprint Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Mol Diagn Ther 11:385-405. 2007
    ....
  23. ncbi request reprint Pharmacogenomics in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, La Coruna, Spain
    Mini Rev Med Chem 2:59-84. 2002
    ..Furthermore, the pharmacogenomics of AD may contribute in the future to optimise drug development and therapeutics, increasing efficacy and safety, and reducing side-effects and unnecessary costs...
  24. ncbi request reprint Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study
    X Anton Alvarez
    EuroEspes Biomedical Research Center, Santa Marta de Babia, 15166 Bergondo, A Coruna, Spain
    Int Clin Psychopharmacol 18:271-8. 2003
    ..These promising preliminary results suggest that Cerebrolysin might be a useful treatment to improve the recovery of patients with traumatic brain damage, and encourage the conduction of confirmatory clinical trials...
  25. doi request reprint Pharmacogenomics of antipsychotics efficacy for schizophrenia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Bergondo, Coruna, Spain
    Psychiatry Clin Neurosci 65:3-19. 2011
    ....
  26. doi request reprint Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury
    X Anton Alvarez
    Department of Neuropharmacology, EuroEspes Biomedical Research Center, Santa Marta de Babío, Bergondo, A Coruna, Spain
    J Neural Transm 115:683-92. 2008
    ..Results of this exploratory study suggest that Cere might improve the functional recovery after brain injury and encourage the conduction of further controlled clinical trials...
  27. ncbi request reprint In vitro regulation of rat derived microglia
    Valter R M Lombardi
    Ebiotec Biotechnology Division, La Coruna, Spain
    Neurotox Res 5:201-12. 2003
    ..These findings suggest that resting ramified microglial cells with neurotrophic activity can be induced with the combination of BME medium and small amounts of extracellular matrix growth promoters...
  28. ncbi request reprint Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease
    Antón Alvarez
    EuroEspes Biomedical Research Center, 15166 A Coruña, Spain
    Neurobiol Aging 28:533-6. 2007
    ..In addition, the combined determination of TNF-alpha and IGF-I might be useful to monitor anti-inflammatory and/or neurotrophic drug effects in AD...